Biotechnology & Life Sciences

Virax Holdings (VHL) is an Australian biotechnology company developing immune based therapies that direct the immune system to treat a broad range of diseases. The company is dedicated to developing a new class of immunotherapeutics to treat widespread, life-threatening diseases of the immune system including HIV/AIDS and other infectious diseases, cancers and autoimmune disease. VLA shares are traded on the Australian stock market.

Viralytics (VLA), formerly Psiron Ltd, is a biotechnology company focused on the development and commercialisation of virotherapy technology for treatment of cancer. The virotherapy technology uses naturaly ocuring viruses such as Coxsackievirus and Echovirus which is associated with the common cold. VLA shares are traded on the Australian stock market.

Tissue Therapies (TIS) is biotechnology company that provides wound healing, tissue repair and cell culture technology through a growth factor platform technology VitroGro®. TIS was incorporated in 2003 and listed on the Australian stock market (ASX) in March 2004. Its head office is situated in Brisbane. The company has agreements with a number of international companies to commercialise its VitroGro® technology.

Stirling Products (STI) specialises in the late stage development and commercialisation of medicated animal feed products for more effective and safer animal growth promotion. STI's products are being positioned as a major influence in reducing the use of antibiotics and steroids by offering a safer and more effective alternative for animal growth promotion across a number of different livestock species. The company was listed on the Australian stock market (ASX) in July 1997 and after delisting, relisted again in 2004.

Solagran (SLA) is a Melbourne-based biotechnology company established in 1995 to commercialise a series of natural, biologically active compounds known as Bioeffectives. Developed at the St Petersburg Forest Technical Academy, Bioeffectives have a wide range of therapeutic and disease preventative applications. Solagran’s R&D team is continuing to develop new Bioeffectives, including powerful antioxidants, immunomodulators, antimicrobials and treatments for prostate disorders.

Select Vaccines (SLT) is targeting global markets for infectious disease diagnostic and vaccine products. Their core commercial objective is the identification of appropriate corporate partnership opportunities. SLT operates in the global life sciences industry, covering pharamceuticals, biotechnology, in-vitro diagnostics, and research tools. The company was listed on the Australian stock market (ASX) in May 1994. Its head office is situated in Victoria.

QRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain management and central nervous system (CNS) disorders. Based on a business strategy to expand the clinical utility and commercial value of marketed and/or existing compounds, QRxPharma’s product portfolio includes both late and early stage clinical drug candidates with well-defined paths to regulatory approval and sales.

Probiotec (PBP) is a brand owner, manufacturer and distributor of a range of over the counter (OTC) pharmaceuticals, complementary medicines and speciality ingredients. The company comprises the management and marketing of quality brands and intellectual property, as well as pharmaceutical manufacturing including contract manufacturing for third parties.

Probiomics (PCC) is a specialist biotechnology company focused on the development of products incorporating PCC®, a strain of Lactic Acid Bacteria (probiotic). Its probiotic products include Progastrim®, sold exclusively to naturopaths, and proTract®, a family of products for intestinal health, diarrhoea and irritable bowel syndrome and for atopic dermatitis. Both these products are listed on the Australian Register of Therapeutic Goods.

Prima Biomed (PRR) is an Australian biotechnology company with a portfolio of products focussed in the therapeutic area of cancer. The company was listed on the Australian stockmarket (ASX) in June 1988. Its headoffice is situated in Armadale, Victoria. Over the years the company has made strategic alliances with Biomira Inc, Medarex Inc, AstraZeneca, Prana and ZymoGenetics.